Lipid-nanoparticle (LNP) and related nanocarrier delivery systems used to formulate and deliver neoantigen vaccines.
This marks the first positive Phase 3 data for an individualized neoantigen therapy or mRNA-based cancer vaccine. Intismeran delivers mRNA encoding tumor-specific mutations identified from a patient's removed tumor, bundled in lipid nanoparticles to train the immune system against recurrence.
A recent review identifies mRNA-lipid nanoparticle systems as offering distinct advantages for personalized cancer vaccines, including rapid manufacturing and potent antigen expression. The authors propose combining these delivery platforms with cytokine engineering and T cell modulation to enhance immunogenicity. This synthesis addresses critical challenges in antigen selection and clinical translation that have hindered broader adoption of personalized vaccines.
West China Hospital is conducting a Phase I, single-arm dose-escalation study (NCT07724106) for NeoOVSV, an mRNA-lipid nanoparticle vaccine in stage II/III ovarian cancer. The trial evaluates safety and immunogenicity when the vaccine is administered alongside standard adjuvant chemotherapy and a PD-1 antibody. This represents an early-stage clinical evaluation of an mRNA platform in combination with checkpoint inhibition.
Scientists developed a carrier-free nanovaccine for hepatocellular carcinoma by self-assembling fluorinated CpG with HCC neoantigen peptides. The resulting 69 nm nanoparticles demonstrated high loading efficiency and enhanced dendritic cell uptake, improving antigen cross-presentation by 2.05-fold in vitro. In vivo, the formulation targeted lymph nodes to orchestrate both innate and adaptive immune responses, offering a biosafe alternative to traditional adjuvant-loaded nanovaccines.
Researchers developed a bivalent mRNA-LNP vaccine targeting AFP and GPC3 neoantigens for hepatocellular carcinoma (HCC). Using spleen-homing CL15H6 LNPs, the formulation achieved superior antigen presentation and co-stimulatory molecule expression on splenic dendritic cells compared to clinical standards. In mouse models, two doses provided complete prophylactic protection against HCC challenge, demonstrating high biosafety and potent cytotoxic T lymphocyte responses.
Personalized neoantigen vaccines are an emerging strategy for cancer immunotherapy, but their effectiveness depends on selecting tumor-specific antigens capable of inducing functional T-cell responses. The VACINUS AI-informed neoantigen prioritization framework previously identif…
West China Hospital has registered a Phase I, single-arm, open-label dose-escalation study for NeoOVIV in stage II/III ovarian cancer patients post-surgery. The personalized mRNA-lipid nanoparticle vaccine will be administered with standard adjuvant chemotherapy and a PD-1 antibody to evaluate safety, tolerability, immunogenicity, and preliminary clinical activity.